Spero Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.90
- 52-Week Range
- $0.87 – $3.08
- Market Cap
- $50.92M
- P/E (TTM)
- —
- EPS (TTM)
- -0.49
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 67.23
- PEG Ratio
- —
- Return on Equity
- -216.41%
- Return on Assets
- 5.35%
- Gross Margin
- 7.43%
- Operating Margin
- 16.91%
- Profit Margin
- -71.02%
- Current Ratio
- —
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- —
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-57.04M
Market Snapshot
About
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections. The company is developing novel therapies designed to address the growing global threat of antibiotic resistance.